Home>>(Ala1)-PAR4 (1-6) (mouse) (trifluoroacetate salt)

(Ala1)-PAR4 (1-6) (mouse) (trifluoroacetate salt) (Synonyms: H-Ala-Tyr-Pro-Gly-Lys-Phe-OH, AYPGKF)

Catalog No.GC41696

(Ala1)-PAR4 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 4 (PAR4) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of mouse PAR4 and residues 60-65 of the full-length sequence with an alanine residue substituted for glycine at position 1/60.

Products are for research use only. Not for human use. We do not sell to patients.

(Ala1)-PAR4 (1-6) (mouse) (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
500μg
$94.00
In stock
1mg
$150.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

(Ala1)-PAR4 (1-6) is a synthetic peptide agonist of proteinase-activated receptor 4 (PAR4) that corresponds to residues 1-6 of the amino terminal tethered ligand sequence of mouse PAR4 and residues 60-65 of the full-length sequence with an alanine residue substituted for glycine at position 1/60. It is 10-fold more potent than PAR4 (1-6) , triggering [3H]inositol phosphate release from KOLF cells expressing human PAR4 at levels comparable to 30 nM thrombin when used at a concentration of 500 μM. (Ala1)-PAR4 (1-6) induces aggregation of human platelets.

Reviews

Review for (Ala1)-PAR4 (1-6) (mouse) (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for (Ala1)-PAR4 (1-6) (mouse) (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.